Rx Importation Is Unsustainable, Distributors Tell Task Force, Because Of Supply/Demand Imbalance
This article was originally published in The Pink Sheet Daily
Executive Summary
The limited availability of Canadian drugs will boost prices of drugs imported to the U.S. if importation were legalized, HDMA tells HHS’ Importation Task Force. High demand for lower-cost foreign drugs would require a controversial government allocation system, McKesson says.
You may also be interested in...
Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says
The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.
Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says
The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.
Drug Importation Infrastructure Already Largely In Place, CVS CEO Says
A bulk importation scheme through certified foreign exporters would require adding safeguards to the existing U.S. distribution system, CVS CEO Ryan tells the HHS importation task force. Primary importation challenge would be ensuring adequate supply